Venus Remedies Hits New 52-Week High of Rs.724.95, Marking Significant Milestone

Strong Momentum Drives Venus Remedies to New Heights

On 21 Nov 2025, Venus Remedies touched an intraday peak of Rs.724.95, setting both a fresh 52-week and all-time high for the stock. This milestone reflects a sustained upward trajectory, with the stock registering gains over the past three consecutive sessions. During this period, Venus Remedies delivered a cumulative return of 27.45%, signalling strong investor confidence in the company’s recent performance.

The stock’s day change stood at 1.62%, outperforming its sector by 2.48%, a notable achievement given the broader market context. Venus Remedies is trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a solid technical foundation supporting the rally.

In comparison, the Sensex opened lower at 85,347.40 points, down by 285.28 points (-0.33%), and was trading at 85,420.15 points (-0.25%) during the same period. The benchmark index remains close to its own 52-week high of 85,801.70, just 0.45% away, and is positioned above its 50-day and 200-day moving averages, reflecting a cautiously optimistic market environment.

Financial Performance Underpinning the Rally

Venus Remedies’ financial metrics provide insight into the factors supporting its recent price movement. The company reported a net profit after tax (PAT) of Rs.20.13 crores for the latest quarter, representing a growth of 473.5% compared to the previous period. This substantial increase in profitability has been a key driver behind the stock’s upward momentum.

The company’s return on capital employed (ROCE) for the half-year period stands at 13.99%, the highest recorded, signalling efficient utilisation of capital resources. Additionally, the inventory turnover ratio for the half-year is at 6.58 times, indicating effective management of stock levels relative to sales.

Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which suggests a conservative capital structure with minimal reliance on borrowed funds. This financial prudence may contribute to the company’s ability to sustain growth and navigate market fluctuations.

Over the past year, Venus Remedies has delivered a total return of 136.72%, significantly outpacing the Sensex’s 10.71% return over the same period. The stock’s 52-week low was Rs.272.20, highlighting the scale of appreciation witnessed in the last twelve months.

Valuation and Market Position

The company’s return on equity (ROE) is recorded at 10.5%, reflecting a reasonable level of profitability relative to shareholder equity. Venus Remedies trades at a price-to-book value of 1.6, which is considered attractive when compared to its peers’ historical valuations. This valuation metric suggests the stock is priced fairly within its sector context.

Venus Remedies has consistently declared positive results for four consecutive quarters, reinforcing a pattern of steady financial performance. The company’s price-to-earnings-to-growth (PEG) ratio stands at 0.1, indicating that the stock’s price growth is supported by its earnings expansion.

Market Context and Risks

Despite Venus Remedies’ impressive performance, the stock’s ownership by domestic mutual funds remains at 0%. This absence of significant holdings by mutual funds, which typically conduct thorough on-the-ground research, may reflect a cautious stance or differing perspectives on the company’s valuation or business model.

While the company’s market capitalisation grade is moderate, the stock’s recent gains and financial results have positioned it as a notable performer within the Pharmaceuticals & Biotechnology sector. The broader market environment, with the Sensex trading near its own highs and maintaining bullish moving averages, provides a supportive backdrop for Venus Remedies’ continued momentum.

Summary

Venus Remedies’ achievement of a new 52-week high at Rs.724.95 marks a significant milestone in its market journey. Supported by strong quarterly profits, efficient capital utilisation, and favourable valuation metrics, the stock has demonstrated resilience and growth over the past year. While broader market conditions remain mixed, Venus Remedies’ performance stands out within its sector, reflecting a combination of solid fundamentals and positive market sentiment.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →